Objective: Although docetaxel is active against gastric cancer, Grade 3 or 4 neutropenia occurs in the majority of patients in Japan when administered at 60 mg/m 2 every 3 weeks. To determine a more convenient and tolerable schedule than the tri-weekly schedule, we conducted a dose-escalation study of bi-weekly docetaxel. In this study, we investigated the maximum-tolerated dose and recommended dose. 
INTRODUCTION
In Japan, S-1 plus cisplatin (CDDP) is recognized as a standard chemotherapy for unresectable or recurrent gastric cancer (GC). This is based on the Japanese Phase III trial that showed a survival benefit of S-1 plus CDDP over S-1 (1) . The median survival time and progression-free survival of S-1 plus CDDP were reported to be 13.0 and 6.0 months, respectively. Despite the survival benefit associated with first-line chemotherapy, the majority of patients experience relapse or disease progression. Second-line chemotherapy and additional therapy are thought to be important for survival benefit. Although docetaxel, paclitaxel and CPT-11 are used for second-or third-line chemotherapy, the standard chemotherapy for GC patients whose disease progressed by prior chemotherapy regimens has not yet been established (2 -7) .
Docetaxel is a semi-synthetic taxane that acts by stabilizing microtubules and is an active drug against GC (8, 9) .
A clinical trial of single-agent docetaxel given at 60 mg/m 2 every 3 weeks demonstrated a 17.1% response rate in advanced GC and 19.5% for its use as a second-line regimen. The dose-limiting toxicity (DLT) of docetaxel when administered at this dose and schedule is severe myelosuppression (10, 11) . Docetaxel exerts activity in various types of tumor including breast, lung and ovarian cancers when administered bi-weekly (12 -14) . The recommended dose (RD) of bi-weekly docetaxel is 50 mg/m 2 for breast cancer, 50 mg/m 2 for lung cancer and 60 mg/m 2 for ovarian cancer. The bi-weekly administration of docetaxel is well tolerated and produces substantially less myelosuppression than is observed with standard docetaxel administration every 3 weeks.
However, a clinical trial of bi-weekly docetaxel administration for GC has not yet been performed. Because patients with advanced GC often suffer from ascites and several gastrointestinal symptoms caused by peritonitis carcinomatosa, a bi-weekly docetaxel regimen given at the RD for GC must be tested.
PATIENTS AND METHODS

ELIGIBILITY
The eligibility criteria were as follows: (i) patients must have histologically confirmed GC from excision or biopsy specimens; (ii) patients must have received more than one prior chemotherapy regimen; (iii) no prior docetaxel was permitted; (iv) prior chemotherapy must have been completed at least 2 weeks prior to study entry; (v) the age range was from 20 to 75 years; (vi) patients were required to have a performance status (PS) of 0 -1 on the Eastern Cooperative Oncology Group scale; (vii) absence of serious organ dysfunction, namely, hemoglobin level 9.0 g/dl, neutrophil count 2000/mm 3 , platelet count 100 000/mm 3 , adequate hepatic function (transaminases ,2 times the upper limit of normal and total bilirubin level ,1.5 mg/dl) and adequate renal function (serum creatinine level ,1.5 mg/dl); (viii) the life expectancy was longer than 2 months; and (ix) all of patients gave their written informed consent to participate in this study.
The exclusion criteria included the following: (i) any organ failure; (ii) active concomitant malignancy; (iii) unfavorable medical condition, such as uncontrolled active infectious disease, cardiac disease or diabetes mellitus; (iv) pregnancy; (v) peripheral neuropathy; (vi) massive ascites or retention of pleural effusion; and (vii) ineligibility to the attending physician.
TREATMENT PLAN
Patients who met the eligibility criteria were given docetaxel every 14 days. Docetaxel was dissolved in 500 ml of saline and was administered intravenously over the cycle of 60 min on day 1. All patients received premedication with 5-hydroxytryptamine3 agonist and dexamethasone (8 mg) intravenously on day 1 and oral dexamethasone (4 mg) given twice daily on days 2 and 3 of each cycle. The prophylactic use of granulocyte colony-stimulating factor and antibiotics was prohibited. This study was conducted using a 3 þ 
DEFINITION OF MAXIMUM-TOLERATED DOSE AND RD
At least three patients were enrolled at each dose level. If a DLT was not observed among these patients, the dose was increased to the next dose level. If two or three patients met the DLT criteria, dose was not increased. If a DLT was observed in one patient, an additional three patients were enrolled. If only one or two of the six patients assigned to this level had DLT, the dose was escalated to the next level.
If two or three of the first three patients or three or more of the six patients had DLT during the initial two cycles, the level was defined as the maximum-tolerated dose (MTD). The RD was defined as the level one step below the MTD.
TREATMENT DELAY AND DISCONTINUATION
Chemotherapy was postponed for any of the following reasons: (i) a leukocyte count ,3000/mm 3 , neutrophil count ,1500/mm 3 and platelet count ,75 000/mm 3 immediately before chemotherapy; (ii) hemoglobin ,8.0 g/dl; and (iii) Grade 2 non-hematologic toxicity (Grade 3 for nausea, vomiting, anorexia and fatigue). Patients continued to receive the assigned treatment at the same dose level bi-weekly, provided that they did not develop progressive disease, refuse further treatment or experience unacceptable toxicity.
EVALUATION AND ASSESSMENT
Before the start of the study, physical examination, PS assessment, complete blood cell counts, chemistry profile, electrolyte determination, chest X-ray, electrocardiography and computed tomography of the abdomen were performed. Patients with measurable lesions had tumor measurements documented within 4 weeks of starting treatment. Physical Table 2 . The median age of the patients was 64.0 (range, 57 -75) years. Ten patients were men and five women. The PS was 0 in eight patients and 1 in seven patients. The histological type of the tumor was intestinal type in 5 patients and diffuse type in 10. Eight patients received prior chemotherapy with one regimen (six with S-1, one with S-1 þ paclitaxel and one with S-1 þ CPT-11), four with two regimens (two with paclitaxel and two with CPT-11 þ CDDP followed by first line S-1 regimen) and three with three regimens including S-1, paclitaxel and CPT-11 þ CDDP. The median number of treatment cycles was 4 (range, 2 -16).
TOXICITIES
The toxicities during the first two cycles are shown in Table 3 . Grade 3 neutropenia was observed in three patients and Grade 4 neutropenia as DLT in only one patient at Level 4. There were no actual episodes of neutropenic fever. Moreover, thrombocytopenia and Grade 3 or 4 anemia were not observed at any dose levels. Grade 3 non-hematologic toxicities were observed only at Level 4. Grade 3 stomatitis was noted in one patient and Grade 3 aspartate aminotransferase (AST)/alanine aminotransferase (ALT) elevation in one patient at Level 4.
The total number of treatment cycles was 75 (12 cycles at Level 1, 13 cycles at Level 2, 24 cycles at Level 3, and 26 cycles at Level 4) . The toxicities in all treatment cycles are summarized in Table 4 . Neutropenia was the most commonly observed hematological toxicity. There were no episodes of neutropenic fever. Non-hematologic toxicities were mild except for stomatitis and AST/ALT elevation during the first two cycles. Neither treatment-related death nor delayed severe toxicities was observed.
MAXIMUM-TOLERATED DOSE AND RECOMMENDED DOSE
At Level 4, Grade 4 neutropenia was found in one patient, Grade 3 stomatitis in one and Grade 3 AST/ALT elevation in one, and these were considered DLTs. On the basis of 
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EFFICACY
Twelve patients had measurable tumors (RECIST). Of these 12 patients, 1 had a partial response at Level 3, yielding a response rate of 8.3%, and 6 patients had stable disease (Table 5) .
DISCUSSION
In most clinical trials of docetaxel against several cancers, a dose of 60 -100 mg/m 2 was administered every 3 weeks (15 -18) . At this dose range, .80% of the patients developed Grade 3 or 4 neutropenia, and hospitalization for the treatment of febrile neutropenia was relatively common. In Japan, two late Phase II clinical studies of tri-weekly docetaxel (60 mg/m 2 ) in patients with advanced GC showed the occurrence of Grade 3 or 4 neutropenia in 81.3 -90.0% of the patients (10, 11) .
Bi-weekly docetaxel has been reported to be effective in various cancers including breast, lung and ovarian cancers as well as to prevent severe myelosuppression (12 -14) . Based on this observation, we investigated whether the bi-weekly administration of docetaxel for GC, which increases the dose intensity of docetaxel, would decrease the appearance and extent of toxicity while maintaining the effect of tri-weekly administration.
The results of this Phase I study for patients having advanced GC with prior chemotherapy demonstrate that the toxicity profile of docetaxel can be markedly altered when this drug is administrated bi-weekly. At Level 4 (50 mg/m 2 ), Grade 4 neutropenia, Grade 3 stomatitis and Grade 3 AST/ ALT elevation appeared as DLTs. Accordingly, Level 4 was judged to be the MTD, and the RD was determined to be one level lower, that is, Level 3 (45 mg/m 2 ). Interestingly, severe myelosuppression, which occurs in a large majority of patients when docetaxel is administrated at 60 mg/m 2 every 3 weeks, was not observed following the bi-weekly schedule besides at the level of the MTD. Non-hematologic toxicity was not severe below the level of the RD. At Level 3, Grade 1 anorexia and Grade 1 alopecia appeared during the first two cycles. In all treatment cycles, cumulative toxicities with repeated cycles of treatment were not observed at the level of the RD. At a bi-weekly dose as high as 45 mg/ m 2 /week (equivalent in dose intensity to 67.5 mg/m 2 every 3 weeks), docetaxel was extremely well tolerated without Grade 3 or 4 toxicities even in previously treated patients.
The efficacy data obtained in this Phase I study are only preliminary. However, these data are not satisfactory on the grounds that many patients have received two or more regimens of prior chemotherapy. Therefore, the efficacy of bi-weekly docetaxel should be investigated by Phase II study.
In conclusion, bi-weekly docetaxel infusion is a possible regimen as salvage chemotherapy for advanced GC. Bi-weekly docetaxel may be more convenient than a triweekly schedule because of the lack of severe toxicities.
Based on the present results, we are planning a Phase II clinical study followed by first-or second-line chemotherapy to evaluate the efficacy of this schedule. Jpn J Clin Oncol 2011;41(6) 751
